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Abstract
Objective—To determine the frequency and risk factors for falls among middle-aged HIV+ and 
HIV− women in the Women's Interagency HIV Study (WIHS).
Methods—We quantified self-report of any and multiple (≥2 falls) in the prior 6 months among 
1,412 HIV+ and 650 HIV− women with mean age 48 years. Logistic regression was used to 
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evaluate associations of demographics, behavioral factors, comorbid conditions, and medications 
with odds of any fall (vs. none) and multiple falls (vs. ≤1 fall).
Results—At least one fall was reported in 263 HIV+ (19%) vs. 119 HIV− (18%) women, and ≥2 
falls reported in 133 HIV+ (9%) vs. 65 HIV− (10%) women. HIV infection was not associated 
with falls in multivariate analyses. Factors independently associated with any fall included age 
(aOR 1.71, 95% CI:1.17-2.49 age 50-59 vs. <39y; aOR 2.26, 95% CI:1.38-3.71 age ≥60 vs. <39), 
current marijuana use (aOR 2.19, 95% CI:1.53-3.13) depressive symptoms (aOR 1.57, 95% CI:
1.21-2.05 for CES-D ≥16), subjective cognitive complaints (aOR 2.19, 95% CI:1.56-3.08), 
neuropathy (aOR 1.59, 95% CI:1.19-2.13), obesity (aOR 1.39, 95% CI:1.08-1.80), number of 
CNS active agents (aOR 2.98, 95% CI:1.90-4.68 for ≥3 agents vs. 0) and WIHS site. Factors 
associated with ≥2 falls included age, marijuana use, number of CNS active agents, subjective 
cognitive complaints, depressive symptoms, neuropathy, and study site.
Conclusions—Falls were associated with factors affecting cognition, but not HIV status in this 
large cohort of women. Longitudinal studies are needed to determine the incidence and 
consequences of falls by HIV status as women age.
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INTRODUCTION
Current paradigms suggest that aging may be accelerated in HIV-infected individuals [1], 
who are more likely to have conditions associated with both aging and falls, such as 
cognitive impairment [2, 3], frailty syndrome [4-6], and polypharmacy [7, 8] when 
compared to HIV-uninfected individuals. Slow gait and poor physical performance are 
common in HIV-infected persons [9, 10], and accelerated gait speed decline has been 
reported in older HIV-infected men [11]. Moreover, in predominantly male injection drug 
users, HIV infection status was associated with reduced physical performance, and both HIV 
and reduced physical performance predicted increased risk of death [12]. Low bone mineral 
density is prevalent in HIV-infected populations, [13] thus the occurrence of falls in HIV-
infected older adults may confer a greater risk of osteoporotic fracture. Several published 
studies show 30-70% increased fracture rates among HIV-infected persons compared with 
uninfected persons [14-16]. We previously demonstrated a higher fracture incidence rate 
among HIV-infected compared with uninfected women in the Women's Interagency HIV 
Study (WIHS), and a greater increase in fracture rate over time for HIV-infected compared 
with uninfected women [17]. While few published data on falls in HIV-infected persons 
exist, middle-aged HIV-infected adults are reported to have unexpectedly high fall risk [18]. 
We conducted this study to determine the frequency of any fall and multiple (≥2) falls 
occurring in the prior 6 months, and determine risk factors associated with falls among HIV-
infected and uninfected women participating in the Women's Interagency HIV Study 
(WIHS).
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METHODS
Study Population
The WIHS is an ongoing, multicenter prospective cohort study of the natural and treated 
history of HIV infection in women, that initially enrolled HIV-infected and uninfected 
women in 1994-95 in six sites nationally (Bronx/Manhattan NY, Brooklyn NY, Chicago IL, 
Washington DC, San Francisco CA, and Los Angeles, CA), with additional enrollment in 
2001-02 and 2011-12. In 2014-15, the WIHS closed its Los Angeles site and added four 
southern U.S. sites: Atlanta GA, Chapel Hill NC, Miami FL, and Birmingham AL/Jackson 
MI. Of the 2067 participants who attended WIHS visit 40 (2014), this analysis includes the 
2062 participants (1,412 HIV+ and 650 HIV− women) with data on falls available. WIHS 
methods and baseline cohort characteristics have been described previously [19]. HIV-
uninfected women were recruited from groups at high risk for HIV infection. At semiannual 
visits, participants complete physical examinations, provide biological specimens, and 
undergo extensive assessment of clinical, behavioral, and demographic characteristics via 
face to-face interviews. Informed consent was obtained using procedures approved by 
committees on human research at each of the collaborating institutions.
In 2014 (at semiannual visit 40), all WIHS participants were asked to report any history of 
fall within the prior 6 months. Fall was defined as: “an unexpected event, including a slip or 
trip, in which you lost your balance and landed on the floor, ground or lower level, or hit an 
object like a table or chair” and participants were further instructed that “Falls that result 
from a major medical event (for example, a stroke or seizure) or an overwhelming external 
hazard (for example, hit by a truck or pushed) should not be included” [20]. Participants 
reporting any fall were asked: i) if they had either “1” or “2 or more” falls in the prior 6 
months, ii) if they sought medical attention for any of these falls, and iii) whether any of 
these falls resulted in fracture. To assess fear of falling (FOF), all participants were asked 
“Are you afraid of falling?” with possible responses of: not at all, a little, quite a bit, or very 
much.
Statistical Analyses
Medians, interquartile ranges, and proportions were derived to summarize study variables, 
depending upon whether they were continuous or categorical. The primary outcomes were: 
report of any fall compared with no fall, and among those who had a fall report of multiple 
falls (2 or more) compared with single fall. Logistic regression models determined factors 
associated with any fall (vs. none) and with multiple falls (vs. ≤1 fall). Bivariate analyses 
evaluating each predictor in association with the outcome were considered for HIV-infected 
and uninfected participants together, and for HIV-infected participants separately using 
univariate logistic regression. Multivariate stepwise logistic models (p to enter and remain = 
0.05) with HIV status (the primary exposure of interest), age (a well-accepted predictor of 
falls) and WIHS site (Brooklyn, Washington D.C., San Francisco, Chicago, Southern sites, 
vs. reference site Bronx) forced into the model were fit. A separate multivariate model, 
restricted to HIV-infected women, was constructed using similar methodology, to evaluate 
the contribution of measures of HIV disease-specific characteristic on fall risk. All p-values 
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reported are two sided from chi-square (for unadjusted proportions), Wilcoxon (for 
unadjusted continuous variables), and Wald tests (for logistic regression).
Our primary exposure of interest was HIV status. Candidate covariates for multivariate 
models included demographic factors, behavioral factors, comorbid conditions, central 
nervous System (CNS) active medications, and HIV-related factors, as follows: 
Demographic factors included: age (40-49, 50-59, and ≥60 vs. <39yrs [reference]), race/
ethnicity (White, Black , vs. other), annual income of $12,000 or less; having graduated 
from high school; and year of WIHS enrollment (2001-2, 2011-14, vs. 1994-5). Behavioral 
factors included HIV transmission risk category (heterosexual, transfusion/unknown/other, 
vs. injection drug [IDU] [reference]); tobacco use (current smoker, former smoker, vs. never 
smoker [reference]); cocaine, crack, or heroin use (current, former, vs. never [reference]); 
injection drug use (current, former, vs. never [reference]); marijuana use (current, former, vs. 
never [reference]); and recent (6 month) alcohol use: heavy (≥14 drinks/wk), moderate (3-13 
drinks/wk), or light (<3 drinks/wk) vs. none [reference]). CNS active medication classes 
included anticonvulsants, antidepressants, antipsychotics, benzodiazepines/sedatives, and 
muscle relaxants. CNS active medications were cumulatively analyzed as the number of 
classes being “currently” used (categorized as 0, 1, 2, or ≥3; [reference group 0 classes]). 
Comorbidities were assessed at the same visit as the falls questionnaire and included the 
following medical conditions associated with falls in published literature: peripheral 
neuropathy (self-report of numbness, tingling, or burning sensations in arms, legs, hands or 
feet lasting for more than two weeks); obesity (body mass index (BMI) ≥30 kg/m2); 
subjective cognitive complaints (defined as self-report over the prior 6 months of either 
major problems with memory or concentration that interfered with normal everyday 
activities and lasted for more than two weeks, or self-report of confusion, getting lost in a 
familiar place or inability to perform routine mental tasks); depressive symptoms (defined as 
Center for Epidemiology Studies Depression (CES-D) of ≥16) [21]; diabetes as previously 
operationalized in WIHS [22]; renal dysfunction (estimated glomerular filtration rate 
(eGFR) <60 using the Modification of Diet in Renal Disease calculation) [23]; hypertension 
(self-report of hypertension in addition to diastolic blood pressure 90 mmHg or greater, 
systolic blood pressure 140 mmHg or greater, or current receipt of antihypertensive 
medication) [24]; and hepatitis C virus infection (defined as positive HCV antibody with 
HCV RNA tested shortly after study entry).
Additional HIV disease specific covariates included: nadir CD4+ count (minimum CD4 
measured at or prior to baseline) and current CD4+ count, current Log10 HIV RNA level, 
current suppressed (<20 c/mL) HIV RNA, prior AIDS-defining illness (ADI), current 
antiretroviral therapy (ART) use, and current and prior use of the following antiretrovirals 
associated with CNS side effects, neuropathy, or lipoatrophy in published literature: 
didanosine, stavudine, zidovudine, or efavirenz.
RESULTS
Participant characteristics
A total of 1,412 HIV-infected and 650 HIV-uninfected women completed the falls 
questionnaire and are included in the current analyses (Table 1). HIV-infected women were 
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older, and more likely to be HCV-infected, have renal dysfunction, and report symptoms of 
peripheral neuropathy. HIV-infected women were less likely than uninfected women to be 
obese, and to report current smoking, current use of marijuana, heroin, cocaine, or crack, 
and heavy alcohol consumption. Among the 1,412 HIV-infected women, 37% reported a 
prior ADI, 88% reported taking ART at the current visit, and 65% had suppressed HIV RNA 
viral load. The overall proportion of women reporting any fall was similar between HIV-
infected and uninfected women, (18.6%, N=263/1,412 for HIV+ and 18.3%, N=119/650 for 
HIV− women, p= 0.12). Among WIHS participants reporting a fall, 31.9% (N=84) of HIV-
infected and 36.1% (N=43) of HIV-uninfected women sought medical attention for an injury 
resulting from their fall (p=0.35), and 3.8% (N=10) of HIV-infected women and 9.2% 
(N=11) in HIV-uninfected women reported fracture (p=0.04).
Factors associated with falls in the Women's Interagency HIV Study Cohort
Univariate analyses of characteristics associated with no fall, single fall, and multiple falls 
are shown in Table 2. There was no difference in the occurrence of either single or multiple 
fall by HIV status, with single fall reported by 9% of HIV-infected and 8% of uninfected 
women, and multiple falls reported by 9% of HIV-infected women and 10% of uninfected 
women (overall p=0.75). Older age, behavioral factors (smoking, substance use, and alcohol 
use) and comorbidities (hypertension, depressive symptoms, subjective cognitive 
complaints, peripheral neuropathy, and obesity) were associated with reported falls (all 
p<0.05, Table 2). Each of the five classes of CNS active medications was associated with 
progressively greater occurrence of falls, as were consequently higher number of categories 
of CNS active medications used. Fear of falling (FOF) was positively associated with single 
and multiple falls. Among women who rated their FOF as “very much”, 13% had a single 
fall in the prior 6 months, and 25% had 2 or more falls, whereas among those with no FOF, 
5% reported single fall and 4% reported ≥2 falls (overall p <0.0001). Among the subset of 
HIV-infected women, measures of HIV disease severity (including CD4+ nadir and prior 
ADI), current CD4+ count, current detectable HIV RNA viral load, and antiretroviral use 
were not associated with falls (Table 2). Unexpectedly, we found that falls differed by site, 
with at the lowest only about 10% of participants at the New York sites reporting sustaining 
a fall versus at the highest 30% of participants in San Francisco; therefore WIHS site was 
included in all multivariate models.
Multivariate analyses of factors associated with any fall
In multivariate analyses for the full cohort, age 50-59 was independently associated with 
higher odds of fall (adjusted Odds Ratio (aOR 1.71, 95% CI:1.17- 2.49 vs. <39), and women 
≥60 years old had over double the odds of any fall compared with those < 39 years (aOR 
2.26, 95% CI:1.38- 3.71) (Table 3). Use of greater numbers of CNS active medications was 
independently associated with increasing fall risk. Compared to use of no CNS active agents, 
use of two medication classes was associated with almost double the odds of falling, and use 
of three or more medication classes was associated with almost triple the odds of falling. 
Women with subjective cognitive complaints were independently over twice as likely to 
report falls than those reporting no cognitive difficulties (aOR 2.19, 95% CI:1.56- 3.08). 
Other factors independently associated with any fall included: WIHS site, current and past 
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marijuana use, depressive symptoms, peripheral neuropathy, and obesity (Table 3). HIV 
infection was not independently associated with fall risk (aOR 1.08, 95% CI: 0.82- 1.42).
Multivariate analyses of factors associated with multiple falls
In multivariate analyses of multiple falls compared with ≤1 fall among HIV-infected and 
uninfected women, independent risk factors were similar to those for any (vs. no) fall (Table 
3), including older age, current or former marijuana use, use of CNS active medications, 
subjective cognitive complaints, depressive symptoms, peripheral neuropathy, and WIHS 
study site. In additional analyses comparing multiple falls with single falls, women reporting 
subjective cognitive complaints had almost double the adjusted odds of multiple vs. single 
falls than women who did not (aOR 1.75, 95% CI:1.05- 2.90), as did those with peripheral 
neuropathy (aOR 1.73, 95%CI:1.08- 2.77), (data not shown). Current crack, cocaine, or 
heroin use was independently associated with multiple (vs. single) falls (aOR 2.89, 95%CI: 
1.32-6.34), whereas HIV infection, age, use of CNS active medications, depressive 
symptoms, obesity, and WIHS site were not (data not shown).
Multivariate analyses of factors associated with falls among HIV-infected women
Among HIV-infected women, those aged 60 or older had double the adjusted risk of any fall 
compared with women <39 years (aOR 2.00, 95%CI: 1.11-3.59) (data not shown). Other 
factors independently associated with any fall among HIV-infected women included WIHS 
site, current (aOR 1.93, 95%CI:1.26- 2.95) and past (aOR 2.92, 95%CI:1.69- 5.07) 
marijuana use, subjective cognitive complaints (aOR 2.31, 95% CI:1.53- 3.47), peripheral 
neuropathy (aOR 1.46, 95% CI:1.04- 2.06), depressive symptoms (aOR 1.49, 95% CI:1.08- 
2.04), and number of CNS active medications (aOR 1.55, 95% CI:1.08-2.23 for one (vs. no) 
class; aOR 2.14, 95% CI:1.40- 3.27 for 2 (vs. no) classes; aOR 2.79, 95% CI:1.63- 4.78 for 
≥3 (vs. no classes). HIV-specific factors (data not shown) including measures of HIV disease 
severity (CD4 nadir and prior ADI), current CD4+ count, suppressed HIV RNA viral load, 
or antiretroviral use (including current ART use, as well as current and prior use of 
didanosine, stavudine, zidovudine, or efavirenz) were not associated with risk of any vs. no 
falls in multivariate analyses
Factors independently associated with risk of multiple falls (vs. ≤1 fall) among HIV-infected 
WIHS participants were similar to those in the complete WIHS cohort and included age 
50-59 years, current and past marijuana use, subjective cognitive complaints, peripheral 
neuropathy, greater number of CNS active medications, and WIHS site (data not shown). 
Current HAART use was associated with half the risk of multiple falls (aOR 0.50, 95%CI: 
0.30- 0.85); other HIV-specific factors were not associated with multiple falls (vs. ≤1 fall) in 
multivariate analyses. In models comparing risks for multiple vs. single falls, only heavy 
alcohol use (aOR 7.28, 95%CI: 1.91- 27.78), current marijuana use (aOR 3.19, 95%CI: 
1.40- 7.28), peripheral neuropathy (aOR 2.17, 95%CI: 1.22- 3.86), and diabetes mellitus 
(aOR 2.04, 95%CI: 1.00-4.16) were associated with multiple falls among HIV-infected 
participants (data not shown).
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DISCUSSION
This is the first study to examine the occurrence of falls and to compare fall frequency and 
risks in women with or at risk for HIV infection. We found that that HIV-infection was not 
associated with increased occurrence of either single or multiple falls, and among HIV 
infected women, measures of HIV-disease or treatment related characteristics did not confer 
additional risk or protection from falls.
Little data exist on fall risks and prevalence in HIV-infected populations, and in published 
and presented studies, estimates have varied widely. Among predominantly male HIV-
infected HAART users with a mean age of 52 years, 30% reported one or more falls within 
12 months and 18% reported recurrent falls, similar to overall fall rates reported among an 
older population (65 years or older) of general U.S. adults [18]. In that study, female gender, 
functional impairment, and multiple medical comorbidities and medications were significant 
predictors of more falls [18]. In a retrospective database review of medical records of 2,000 
HIV-infected outpatients in Louisiana, only 32 falls were identified within 12 months, and 
polypharmacy (>5 medications), >3 medical comorbidities, and nonadherence to ART were 
associated with increased fall risk [25]. Similar to our study, a Multicenter AIDS Cohort 
Study (MACS) study of bone strength among men aged 50-79 years reported similar 
numbers of single fall and multiple falls over 2 years among HIV-infected and uninfected 
men (27% reported single fall for HIV+ and 23% for HIV-; multiple falls in 11% of HIV+ 
and 9% of HIV− men) [26].
It is well established that among older persons in the U.S., one-third fall annually [27, 28], 
with 10% of these falls resulting in injury requiring medical attention [27, 29]. By 
comparison among our 198 WIHS participants 60 years or older, about 25% reported having 
sustained a fall in the prior 6 months; however because we collected falls data over 6 months 
rather than 12 months, these numbers may represent an underestimation of annual rate of 
falls occurrence. Approximately one-third of woman having at least one fall had a fall that 
resulted in injury requiring medical attention, although the proportion of falls resulting in 
injury did not differ by HIV status.
We found that illicit drug use was also associated with more falls; marijuana use in particular 
was associated with both single and multiple falls. Our finding that current use of crack, 
cocaine, or heroin use was associated with multiple (vs. single falls) may in part explain the 
underlying reason for the increased incidence of fracture associated with cocaine use and 
injection drug use we previously reported in the WIHS cohort [17]. Among HIV-infected 
women, heavy alcohol use was also associated with multiple (vs. single) falls. Alcohol 
and/or illicit drug use may increase fall risk through over-sedation, dizziness, or impairment 
in gait, balance, judgment, or cognition. Combined alcohol and prescription medication use 
may also result in an increase in blood alcohol levels, altered metabolism of other 
medications, exacerbation of adverse effects of medications, decreased effectiveness of 
medications, or worsening of underlying conditions (including hypertension, diabetes, 
depression, seizures, and liver disease) [30]. Prescription opioid use has been associated 
with increased fall [31, 32] and fracture [32-35] risk, however fall or fracture risks 
associated with illicit opioid use or marijuana use among older persons have not been 
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evaluated to date. Our data suggest that marijuana use in particular may be an important 
consideration when evaluating fall risk in older populations.
Falls and fractures are considered as geriatric syndromes, clinical conditions with shared risk 
factors that are highly prevalent in the elderly, and associated with poor outcomes, including 
disability, frailty, reduced quality of life, loss of independence, and mortality [36, 37]. Many 
studies have described premature occurrence of medical comorbidities associated with aging 
in HIV-infected populations compared with the general population [1, 38, 39], including 
multimorbidity [1, 40], fracture [14-16], and frailty [4-6]. Because low BMD is prevalent in 
HIV-infected populations, falls may be more likely to result in fractures in this population. 
In a 10 year French national cohort study of treated HIV-infected patients with a median age 
of 36 years, 81% of the fractures that occurred were caused by sustaining a fall or other 
trauma; however no comparison group of uninfected persons was included [41]. Notably, we 
found an association between HAART use and reduced risk of multiple falls among HIV-
infected women, which has not been previously reported. While we did not observe higher 
occurrence of falls among HIV-infected women, prospective longitudinal studies are need to 
determine whether falls result in greater likelihood of injury in HIV-infected than uninfected 
women, whether overall risk for fall-related injury increases disproportionately with age 
among HIV-infected vs. uninfected women, and whether HAART use reduces risk of 
recurrent falls among HIV-infected persons.
Ours is the first study of aging HIV-infected and uninfected women to characterize the fall-
risk associated with number and type of medications. We found that concurrent use of 
multiple CNS active agents was associated with greater risk of falls. Many of these agents 
have anticholinergic activity, which has been associated with worse cognitive and functional 
performance as well as recurrent and injurious falls through gait and balance impairment 
among older adults [42, 43]. The associations between sedatives/hypnotics and anti-
depressants with both falls and fall-related injuries has been well documented in elderly 
populations, as have those with antipsychotics, anticonvulsants, antihypertensives, and 
opioids [44-47]. Moreover, polypharmacy, often defined as the use of five or more 
prescribed medications, is a well-established risk factor for falls and fall-related injury, 
despite adjusting for fall risk inducing drugs or medical comorbidities [29, 48-50]. Although 
polypharmacy is common in HIV-infected populations and increases with age [7, 8]; the risk 
of harm associated with polypharmacy is greatly understudied in HIV-infected persons. 
Studies have shown increased fall risk associated with greater numbers of prescribed 
medications among HIV-infected persons; however these studies were limited by a lack of 
HIV-uninfected controls and few female participants [18, 26]. Identification of adverse 
effects associated with specific medication classes and polypharmacy is necessary in order 
to determine how best to mitigate risks and maximize benefits of each prescribed 
medication.
Unexpectedly, we found significant geographical differences in fall occurrence ranging from 
~10% in the New York sites to 30% at San Francisco. Both New York City (NYC)-based 
WIHS sites in particular demonstrated reduced falls occurrence compared with other study 
sites. Although we are unable to explain these geographic differences in falls occurrence, we 
speculate that these differences may be in part due to the greater participant use of public 
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transportation and more time spent walking in NYC, compared with other sites in which 
driving may be a more frequent mode of transportation, however we are unable to test this 
theory. Additional possibilities include geographic variation of environmental factors, 
weather conditions or seasonality, or physical activity across sites.
Our study has several limitations. Fall ascertainment was based on participants’ self-reportof 
events in the prior 6 months, which may result in underreporting of falls, particularly in 
older participants or those with cognitive impairment. Additionally, self-report of cognitive 
difficulty is a crude measure and is likely to capture only those with significant impairment, 
which is apparent to the participants themselves. We do not have complete data on measures 
of frailty, physical activity, or disability, nor on several factors associated with fall risk, such 
as vision problems, urinary incontinence, history of stroke or heart failure, polypharmacy, 
and orthostatic hypotension. We also do not have data on time of year when falls occurred, 
nor circumstances of fall, such as activity at the time of fall, conditions associated with fall 
(i.e. wet floor, icy sidewalk) or location (i.e. indoor vs. outdoor). Because this is a cross-
sectional study, we are unable to ascertain temporal relationships between fear of falling, 
quality of life, and physical activity with fall, and in order to avoid biases associated with 
reverse-causality, we excluded these measures from analyses. Last, analyses of medication 
risks associated with falls may be subject to confounding by indication.
CONCLUSIONS
We found that the occurrence of self-reported falls is similar in HIV-infected and HIV-
uninfected women with a mean age of 48, and that HIV-disease or treatment related 
characteristics were not associated with fall risk among those with HIV infection. We 
identified a number of modifiable risk factors for falls, including use of multiple CNS active 
medications and substance abuse, which could be important areas to target in falls 
prevention efforts as HIV-infected women age. Longitudinal studies are needed to determine 
whether the incidence and consequence of falls will be greater in HIV-infected than 
uninfected women as they age.
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Table 1
Characteristics of Women's Interagency HIV Study Participants
Characteristic HIV-infected (N=1412) HIV-uninfected (N=650) P value*
Age (years) < 0.0001
    <39 236 (16.7%) 164 (25.2%)
    40-49 509 (36.1%) 220 (33.9%)
    50-59 531 (37.6%) 204 (31.4%)
    ≥60 136 (9.6%) 62 (9.5%)
WIHS Site <0.0001
    Bronx / Manhattan 237 (16.8%) 125 (19.2%)
    Brooklyn 238 (16.9%) 90 (13.9%)
    Washington DC 204 (14.5%) 86 (13.2%)
    Chicago 211 (14.9%) 75 (11.5%)
    San Francisco 207 (14.7%) 102 (15.7%)
    Southern sites 315 (22.3%) 172 (26.5%)
Race 0.28
    White 224 (16.0%) 86 (13.4%)
    Black 1002 (71.6%) 479 (74.5%)
    Other 173 (12.%) 78 (12.1%)
HIV transmission risk category < 0.0001
    Injection Drug Use 233 (16.7%) 88 (13.7%)
    Heterosexual risk 577 (41.5%) 181 (28.2%)
    Transfusion risk/ Unknown/other 582 (41.8%) 373 (58.1%)
Smoking status < 0.0001
    Never 455 (32.2%) 176 (27.1%)
    Past 421 (29.8%) 159 (24.5%)
    Current 536 (38.0%) 315 (48.5%)
Cocaine, crack or heroin use < 0.0001
    Never 667 (47.24%) 289 (44.5%)
    Past 662 (46.9%) 283 (43.5%)
    Current 83 (5.9%) 78 (12.0%)
Marijuana use 0.0003
    Never 476 (33.7%) 207 (31.9%)
    Past 690 (48.9%) 281 (43.2%)
    Current 246 (17.4%) 162 (24.9%)
Recent alcohol use < 0.0001
    None 765 (54.8%) 286 (44.5%)
    Light (< 3 drinks/wk) 475 (34.0%) 220 (34.2%)
    Moderate (3-13 drinks/wk) 57 (4.1%) 36 (5.6%)
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Characteristic HIV-infected (N=1412) HIV-uninfected (N=650) P value*
    Heavy (≥14 drinks/wk) 99 (7.1%) 101 (15.7%)
Comorbidities
    Hepatitis C Virus infection 172 (12.2%) 46 (7.1%) 0.0005
    Diabetes Mellitus 265 (18.8%) 131 (20.3%) 0.43
    Hypertension 683 (48.4%) 320 (49.2%) 0.72
    Renal dysfunction (eGFR <60) 153 (11.0%) 42 (6.5%) 0.002
    Depressive symptoms (CESD ≥16) 440 (31.5%) 203 (31.6%) 0.96
    Subjective cognitive complaints 162 (11.5%) 81 (12.5%) 0.52
    Peripheral neuropathy 291 (20.6%) 91 (14.0%) 0.0003
    Obesity (≥30kg/m2) 650 (47.1%) 373 (58.9%) < 0.0001
Current use of CNS active medications by category
    Anticonvulsants 188 (13.3%) 58 (8.9%) 0.004
    Antidepressants 385 (27.3%) 115 (17.7%) < 0.0001
    Antipsychotics 143 (10.1%) 78 (12.0%) 0.20
    Benzodiazepines and other sedatives 174 (12.3%) 80 (12.3%) 0.99
    Muscle relaxants 55 (3.9%) 44 (6.8%) 0.005
Categories of CNS active medication used 0.014
    0 833 (59.0%) 430 (66.2%)
    1 319 (22.6%) 113 (17.4%)
    2 174 (12.3%) 69 (10.6%)
    ≥3 86 (6.1%) 38 (5.9%)
Reported fear of falling 0.93
    Not at all 876 (62.0%) 408 (62.8%)
    A little 296 (21.0%) 131 (20.2%)
    Quite a bit 102 (7.2%) 44 (6.8%)
    Very much 138 (9.8%) 67 (10.3%)
Number of falls within 6 months 0.75
    0 1149 (81.4%) 531 (81.7%)
    1 130 (9.2%) 54 (8.3%)
    ≥2 133 (9.4%) 65 (10.0%)
HIV disease related characteristics
    AIDS defining illness ever 517 (36.6%) N/A
    Current CD4+ cell count (cells/μl), median (IQR) 589 (385-808) N/A
    Nadir CD4+ cell count (cells/μl), median (IQR) 274 (146-462) N/A
    Suppressed HIV RNA viral load (<20c/mL) 907 (65.4%) N/A
    Current ART use 1240 (87.8%) N/A
    Efavirenz use N/A
        Never 764 (54.1%) N/A
        Current/former 648 (45.9%) N/A
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Characteristic HIV-infected (N=1412) HIV-uninfected (N=650) P value*
    Zidovudine Use N/A
        Never 691 (48.9%) N/A
        Current/former 721 (51.1%) N/A
    Didanosine use N/A
        Never 1065 (75.4%) N/A
        Current/former 347 (24.6%) N/A
    Stavudine use N/A
        Never 988 (70.0%) N/A
        Current/former 424 (30.0%) N/A
*Compares HIV− to HIV+ with independent samples t-test or Wilcoxon test for continuous variables and with Chi-square test for categorical 
variables
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Table 2
Factors Associated with Falls in the Women's Interagency HIV Study
No Fall (N=1680) Single Fall (N=184) Multiple Falls (N=198) P value*
HIV status 0.75
    HIV-uninfected 531 (31.6%) 54 (29.3%) 65 (32.8%)
    HIV-infected 1149 (68.4%) 130 (70.7%) 133 (67.2%)
Age (years) 0.0001
    <39 346 (20.6%) 32 (17.4%) 22 (11.1%)
    40-49 614 (36.5%) 48 (26.1%) 67 (33.8%)
    50-59 571 (34.0%) 77 (41.8%) 87 (43.9%)
    ≥60 149 (8.9%) 27 (14.7%) 22 (11.1%)
WIHS Site <0.0001
    Bronx / Manhattan 324 (19.3%) 20 (10.9%) 18 (9.1%)
    Brooklyn 299 (17.8%) 12 (6.5%) 17 (8.6%)
    Washington DC 235 (14.0%) 28 (15.2%) 27 (13.6%)
    San Francisco 218 (13.0%) 29 (15.8%) 39 (19.7%)
    Chicago 216 (12.9%) 48 (26.1%) 45 (22.7%)
    Southern sites 388 (23.1%) 47 (25.5%) 52 (26.3%)
Race 0.55
    White 251 (15.1%) 26 (14.3%) 33 (16.9%)
    Black 1208 (72.6%) 129 (70.9%) 144 (73.8%)
    Other 206 (12.4%) 27 (14.8%) 18 (9.2%)
HIV transmission risk category 0.0001
    Injection Drug Use 237 (14.3%) 38 (21.1%) 46 (23.6%)
    Heterosexual risk 607 (36.6%) 72 (40.0%) 79 (40.5%)
    Transfusion risk/Unknown/Other 815 (49.1%) 70 (38.9%) 70 (35.9%)
Smoking status 0.0009
    Never 544 (32.4%) 45 (24.5%) 42 (21.2%)
    Past 476 (28.3%) 49 (26.6%) 55 (27.8%)
    Current 660 (39.3%) 90 (48.9%) 101 (51.0%)
Cocaine, crack or heroin use < 0.0001
    Never 822 (48.9%) 74 (40.2%) 60 (30.3%)
    Past 743 (44.2%) 97 (52.7%) 105 (53.0%)
    Current 115 (6.8%) 13 (7.1%) 33 (16.7%)
Marijuana use <0.0001
    Never 598 (35.6%) 47 (25.5%) 38 (19.2%)
    Past 787 (46.8%) 91 (49.5%) 93 (47.0%)
    Current 295 (17.6%) 46 (25.0%) 67 (33.8%)
Recent alcohol use 0.028
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No Fall (N=1680) Single Fall (N=184) Multiple Falls (N=198) P value*
    None 870 (52.3%) 90 (49.5%) 91 (46.9%)
    Light 562 (33.8%) 72 (39.6%) 61 (31.4%)
    Moderate 76 (4.6%) 7 (3.8%) 10 (5.2%)
    Heavy 155 (9.3%) 13 (7.1%) 32 (16.5%)
Comorbidities
    Hepatitis C Virus infection 167 (9.9%) 26 (14.1%) 25 (12.6%) 0.13
    Diabetes Mellitus 310 (18.5%) 37 (20.1%) 49 (24.7%) 0.10
    Hypertension 779 (46.4%) 104 (56.5%) 120 (60.6%) <0.0001
    Renal dysfunction (eGFR <60) 149 (9.0%) 21 (11.5%) 25 (12.9%) 0.14
    Depressive symptoms (CESD ≥ 16) 450 (27.1%) 85 (46.7%) 108 (55.4%) <0.0001
    Subjective cognitive complaints 142 (8.5%) 36 (19.6%) 65 (32.8%) < 0.0001
    Peripheral neuropathy 257 (15.3%) 48 (26.1%) 77 (38.9%) <0.0001
    Obesity (≥30kg/m2) 815 (49.6%) 106 (59.2%) 102 (53.4%) 0.039
Current use of CNS active medications by category
    Anticonvulsants 159 (9.5%) 37 (20.1%) 50 (25.3%) <0.0001
    Antidepressants 346 (20.6%) 72 (39.1%) 82 (41.4%) <0.0001
    Antipsychotics 145 (8.6%) 34 (18.5%) 42 (21.2%) <0.0001
    Benzodiazepines/sedatives 179 (10.7%) 37 (20.1%) 38 (19.2%) <0.0001
    Muscle relaxants 63 (3.8%) 12 (6.5%) 24 (12.1%) < 0.0001
Number of categories of CNS active medication used <0.0001
    0 1114 (66.3%) 78 (42.4%) 71 (35.9%)
    1 327 (19.5%) 49 (26.6%) 56 (28.3%)
    2 168 (10.0%) 35 (19.0%) 40 (20.2%)
    3 57 (3.4%) 15 (8.2%) 24 (12.1%)
    4 12 (0.7%) 7 (3.8%) 7 (3.5%)
    5 2 (0.1%) 0 0
Reported fear of falling <0.0001
    Not at all 1170 (69.6%) 65 (35.3%) 49 (24.7%)
    A little 307 (18.3%) 65 (35.3%) 55 (27.8%)
    Quite a bit 77 (4.6%) 27 (14.7%) 42 (21.2%)
    Very much 126 (7.5%) 27 (14.7%) 52 (26.3%)
HIV disease related characteristics (N=1412)
AIDS defining illness ever 412 (35.9%) 47 (36.2%) 58 (43.6%) 0.21
Current CD4+ count (cells/μl), median (IQR) 585 (389-808) 639 (356-804) 590 (382-824) 0.93
Nadir CD4+ count (cells/μl), median (IQR) 270 (144-456) 295 (154-485) 303 (156-483) 0.44
Suppressed HIV RNA viral load (<20c/mL) 389 (34.5%) 41 (31.5%) 49 (38.3%) 0.52
Current ART use 1016 (88.4%) 115 (88.5%) 109 (82.0%) 0.094
Didanosine use 0.25
    Never 858 (74.7%) 100 (76.9%) 107 (80.5%)
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No Fall (N=1680) Single Fall (N=184) Multiple Falls (N=198) P value*
    Former 274 (23.8%) 30 (23.1%) 26 (19.5%)
    Current 17 (1.5%) 0 0
Stavudine use
    Never 795 (69.2%) 93 (71.5%) 100 (75.2%) 0.60
    Former 351 (30.5%) 37 (28.5%) 33 (24.8%)
    Current 3 (0.3%) 0 0
Zidovudine use 0.17
    Never 547 (47.6%) 72 (55.4%) 72 (54.1%)
    Former 534 (46.5%) 54 (41.5%) 57 (42.9%)
    Current 68 (5.9%) 4 (3.1%) 4 (3.0%)
Efavirenz use 0.76
    Never 625 (54.4%) 72 (55.4%) 67 (50.4%)
    Former 263 (22.9%) 28 (21.5%) 37 (27.8%)
    Current 261 (22.7%) 30 (23.1%) 29 (21.8%)
*Comparison between groups using Chi-Square test for categorical variables and Wilcoxon test for continuous variable
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Table 3
Predictors of Any Fall (vs. No Falls) and Multiple (≥2) Falls (vs. ≤1 Fall) in the Women's Interagency HIV 
Study
Any Fall
Multivariate OR (95% CI)
Multiple Falls
Multivariate OR (95% CI)
HIV infection 1.08 (0.82, 1.42) 0.84 (0.60, 1.18)
Age (years)
    <39 Reference Reference
    40-49 1.18 (0.81, 1.74) 1.69 (0.99, 2.86)
    50-59 1.71 (1.17, 2.49)** 1.96 (1.16, 3.31)**
    ≥60 2.26 (1.38, 3.71)* 2.08 (1.05, 4.10)*
Marijuana use
    Never Reference Reference
    Past 1.55(1.13, 2.14)** 1.73 (1.11, 2.68)**
    Current 2.19 (1.53, 3.13)*** 2.60 (1.64, 4.13)***
Categories of CNS active medications
    0 Reference Reference
    1 1.59 (1.17, 2.15)** 1.61 (1.08, 2.40)*
    2 1.98 (1.38, 2.84)*** 1.81 (1.14, 2.85)**
    ≥3 2.98 (1.90, 4.68)*** 2.68 (1.57, 4.57)***
Depressive symptoms (CESD ≥ 16) 1.57 (1.21, 2.05)*** 1.56 (1.10, 2.19)**
Subjective cognitive complaints 2.19 (1.56, 3.08)*** 2.45 (1.66, 3.62)***
Peripheral neuropathy 1.59 (1.19, 2.13)*** 1.89 (1.33, 2.70)***
Obesity (≥30kg/m2) 1.39 (1.08, 1.80)* -
Comparison group for analyses of any fall represents participants reporting no fall; comparison group for analyses of multiple (≥) falls represents 
participants reporting no fall or single fall. All models are adjusted for WIHS site.
*p<= 0.05
**p<= 0.01
***p<= 0.001
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